Most Favored Nation (MFN) Drug Pricing Could Cost Cancer Patients Future Breakthroughs
GCCA CEO speaks on the risks of MFN policy.
1 min read
At ASCO 2026, Andrew Spiegel of the Global Colon Cancer Association and Marcia Horn of the International Cancer Advocacy Network explain why many patient advocates are concerned that proposals to codify Most Favored Nation (MFN) prescription drug pricing could unintentionally reduce investment in future cancer research and slow the development of new treatments.